Table 4

Use of gastroprotection, transfusion requirements and length of hospitalisation with regard to gastropathy risk factors in patients admitted for non-steroidal anti-inflammatory drug (NSAID)-induced gastropathy

Risk factorPatients, n (%)Gastroprotection use, n (%)p ValueBlood transfusion, n (%)p ValueMean (SD) hospital stay, daysp Value
Age
 >60 years37 (59.7)18 (48.6)0.00121 (56.8)0.0266.1 (4.5)0.022
 ≤60 years25 (40.3)2 (8.0)7 (28.0)4.1 (1.9)
Sex
 Men32 (51.6)8 (25.0)0.20716 (50.0)0.4295.9 (4.6)0.145
 Women30 (48.4)12 (40.0)12 (40.0)4.5 (2.5)
Concomitant medication*
 Yes24 (38.7)13 (54.2)0.00314 (58.3)0.0985.6 (3.0)0.548
 No38 (61.3)7 (18.4)14 (36.8)5.0 (4.2)
History†
 Yes9 (14.5)6 (66.7)0.0175 (55.5)0.4985.8 (2.9)0.659
 No53 (85.5)14 (26.4)23 (43.4)5.2 (3.9)
Comorbidities‡
 Yes15 (24.2)9 (60.0)0.00812 (80.0)0.0027.2 (2.9)0.021
 No47 (75.8)11 (23.4)16 (34.0)4.5 (3.8)
  • *Concomitant use of systemic corticosteroids, oral anticoagulants, clopidogrel or other NSAIDs (including ASA as antiplatelet).

  • †Personal medical history of peptic ulcer with/without complication (gastrointestinal bleeding, pyloric stenosis and perforation).

  • ‡Cerebrovascular disease, chronic obstructive lung disease, cirrhosis, coronary disease, heart failure or renal failure.

  • ASA, acetylsalicylic acid.